August 27, 2017New England Journal of Medicine9,353 citationsOpen Access
View Full PaperAntiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Key Points
- The aim is to evaluate the efficacy of canakinumab in reducing recurrent cardiovascular events in patients with atherosclerotic disease.
- Randomized trial design
- Patients received 150 mg of canakinumab every 3 months
- Compared to placebo for assessing the impact on cardiovascular events.
- Canakinumab significantly lowered the rate of recurrent cardiovascular events compared to placebo (exact rates not provided)
- Efficacy was independent of lipid-level lowering effects.
Abstract
Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846 .).
Expert Takes2 quotes
1/2
“The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) trial, which randomized 10,061 patients post–myocardial infarction (MI) with hs-CRP ≥2 mg/L to either canakinumab (an IL-1β antibody) or placebo over a 3.7-year follow-up period, provided clinical proof of the role of inflammatio...”
ACC Journal ScanView source